Patient Preference for Placebo, Acetaminophen (paracetamol) or Celecoxib Efficacy Studies (PACES): two randomised, double blind, placebo controlled, crossover clinical trials in patients with knee or hip osteoarthritis. Issue 8 (13th April 2004)

• Record Type: Journal Article
• Authors: Pincus, T; Koch, G; Lei, H; Mangal, B; Sokka, T; Moskowitz, R; Wolfe, F; Gibofsky, A; Simon, L; Zlotnick, S; Fort, J G
• Is Part Of: Annals of the rheumatic diseases. Volume 63:Issue 8(2004)
• Page Start: 931
• Page End: 939
• Publication Date: 2004-04-13
• Subjects: MDHAQ, Multidimensional Health Assessment Questionnaire -- NSAIDs, non-steroidal anti-inflammatory drugs -- SF-36, Short Form-36 -- WOMAC, Western Ontario McMaster Osteoarthritis Index; celecoxib -- osteoarthritis -- acetaminophen -- placebo -- WOMAC -- pain visual analogue scale -- paracetamol; Rheumatism -- Periodicals; 616.723005
• DOI: 10.1136/ard.2003.020313
• Languages: English
• ISSNs: 0003-4967

Abstract

Abstract : Background: Acetaminophen (paracetamol) is recommended as the initial pharmacological treatment for knee or hip osteoarthritis. However, survey and clinical trial data indicate greater efficacy for non-steroidal anti-inflammatory drugs and cyclo-oxygenase-2 specific inhibitors. Design: Two randomised, double blind, placebo controlled, crossover multicentre clinical trials, Patient Preference for Placebo, Acetaminophen or Celecoxib Efficacy Studies (PACES). Patients: Osteoarthritis of knee or hip. Intervention: "Wash out" of treatment; randomisation; 6 weeks of celecoxib 200 mg/day, acetaminophen 1000 mg four times a day, or placebo; second "wash out;" crossover to 6 weeks of second treatment. Measurements: Western Ontario McMaster Osteoarthritis Index (WOMAC), visual analogue pain scale, patient preference between two treatments. Results: Celecoxib was more efficacious than acetaminophen in both periods in both studies; WOMAC and pain scale scores differed at p<0.05 in period II and both periods combined of PACES-a and in periods I and II and both periods combined in PACES-b, but not in period I of PACES-a. Acetaminophen was more efficacious than placebo, generally p<0.05 in PACES-b, and >0.05 in PACES-a. Patient preferences were 53% celecoxib v 24% acetaminophen in PACES-a (p<0.001) and 50% v 32% in PACES-b (p = 0.009); 37% acetaminophen v 28% placebo in PACES-a (p = 0.340) and 48% v 24% in PACES-b (p = 0.007). No clinically or statistically significant differences were seen in adverse events or tolerability among the three treatment groups. Conclusions: Greater efficacy was seen for celecoxib v acetaminophen v placebo, while adverse events and tolerability were similar. Variation in results and statistical significance in the two different trials are of interest.